{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T06:15:16Z","timestamp":1783318516125,"version":"3.54.6"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Bethesda III thyroid nodules represent a heterogeneous cytological category with an estimated malignancy risk of 13\u201330%, creating uncertainty in clinical decision-making. This study aimed to characterise surgically resected Bethesda III thyroid nodules in a multicentre cohort and to develop a simple preoperative risk score for malignancy prediction using routinely available variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective, observational, multicentre study across four tertiary hospitals in the Region of Murcia, Spain. Adults with Bethesda III thyroid nodules who underwent thyroidectomy between 2020 and 2025 were included. Clinical, biochemical, ultrasonographic, cytological, and histopathological variables were analysed using univariate and multivariable logistic regression. A simplified integer-based risk score was derived from the independent predictors identified in the final model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighty-five nodules were included, with a malignancy rate of 23.5%. Three preoperative variables remained independently associated with malignancy: moderate-to-high ultrasound risk, nuclear atypia on fine-needle aspiration, and lymphocytic thyroiditis on fine-needle aspiration. These predictors were incorporated into a practical score ranging from 0 to 15 points. The model showed acceptable apparent discrimination and calibration, although internal bootstrap validation indicated that cautious interpretation is required because of the limited sample size. A cut-off of 10 points or higher provided the best overall diagnostic performance, and the predicted probability of malignancy ranged from 2.4% to 74.8% across the score spectrum.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>In this multicentre cohort of surgically resected Bethesda III thyroid nodules, a simple three-item exploratory score showed promising performance for preoperative malignancy risk stratification. This tool may help support clinical decision-making using variables available in routine practice, although external validation in larger independent cohorts is required before routine clinical implementation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1863739","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T05:37:57Z","timestamp":1783316277000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Preoperative risk score for malignancy in Bethesda III thyroid nodules: a multicentre retrospective study"],"prefix":"10.3389","volume":"17","author":[{"given":"Manuel","family":"Carpio-Salmer\u00f3n","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Nutrition, Santa Luc\u00eda University General Hospital","place":["Cartagena, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"T\u00e9bar-Caballero","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Reina Sof\u00eda Hospital","place":["Murcia, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Benito","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine and Epidemiology, Clinical Institute of Medicine and Dermatology (ICMiD), Hospital Cl\u00ednic de Barcelona","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemente","family":"Garc\u00eda-Hidalgo","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hospital Morales Meseguer","place":["Murcia, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Kyriakos","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Santa Luc\u00eda University General Hospital","place":["Cartagena, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"R\u00edos-Vergara","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Santa Luc\u00eda University General Hospital","place":["Cartagena, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gin\u00e9s","family":"Luengo-Gil","sequence":"additional","affiliation":[{"name":"Group of Molecular Pathology and Pharmacogenetics, Pathology Department, IMIB-Pascual Parrilla, Hospital General Universitario Santa Luc\u00eda","place":["Cartagena, Spain"]},{"name":"Health Sciences Faculty, Universidad Cat\u00f3lica de Murcia (UCAM)","place":["Guadalupe, Murcia, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Carazo-Casas","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Ram\u00f3n y Cajal Hospital","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Casas-Miras","sequence":"additional","affiliation":[{"name":"General University Hospital Santa Luc\u00eda, Pathological Anatomy","place":["Cartagena, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Mar\u00edn-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Santa Luc\u00eda University General Hospital","place":["Cartagena, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Bel\u00e9n","family":"Arroyo","sequence":"additional","affiliation":[{"name":"Group of Molecular Pathology and Pharmacogenetics, Pathology Department, IMIB-Pascual Parrilla, Hospital General Universitario Santa Luc\u00eda","place":["Cartagena, Spain"]},{"name":"Health Sciences Faculty, Universidad Cat\u00f3lica de Murcia (UCAM)","place":["Guadalupe, Murcia, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"B2","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/j.1365-2362.2009.02162.x","article-title":"Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination","volume":"39","author":"Guth","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2008.09.019","article-title":"Epidemiology of thyroid nodules","volume":"22","author":"Dean","year":"2008","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00139-5","article-title":"Management of thyroid nodules","volume":"10","author":"Alexander","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-23-0067","article-title":"2023 European Thyroid Association clinical practice guidelines for thyroid nodule management","volume":"12","author":"Durante","year":"2023","journal-title":"Eur Thyroid J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2016.110","article-title":"The changing incidence of thyroid cancer","volume":"12","author":"Kitahara","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/js.2018-00287","article-title":"Influence of Hashimoto thyroiditis on the development of thyroid nodules and cancer in children and adolescents","volume":"3","author":"Radetti","year":"2019","journal-title":"J Endocr Soc"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.envpol.2022.120478","article-title":"Exposure to Bisphenol A increases Malignancy risk of thyroid nodules in overweight\/obese patients","volume":"316","author":"Marotta","year":"2023","journal-title":"Environ pollut"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacr.2017.01.046","article-title":"ACR thyroid imaging, reporting and data system (TI-RADS): white paper of the ACR TI-RADS committee","volume":"14","author":"Tessler","year":"2017","journal-title":"J Am Coll Radiol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1159\/000478927","article-title":"European Thyroid Association guidelines for ultrasound Malignancy risk stratification of thyroid nodules in adults: The EU-TIRADS","volume":"6","author":"Russ","year":"2017","journal-title":"Eur Thyroid J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0500","article-title":"The 2017 bethesda system for reporting thyroid cytopathology","volume":"27","author":"Cibas","year":"2017","journal-title":"Thyroid"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2023.0141","article-title":"The 2023 bethesda system for reporting thyroid cytopathology","volume":"33","author":"Ali","year":"2023","journal-title":"Thyroid"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0419","article-title":"Cancer risk associated with nuclear atypia in cytologically indeterminate thyroid nodules: A systematic review and meta-analysis","volume":"28","author":"Valderrabano","year":"2018","journal-title":"Thyroid"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.endien.2018.07.010","article-title":"Prevalence and associated Malignancy of Bethesda category III cytologies of thyroid nodules assigned to the \u201ccytological atypia\u201d or \u201carchitectural atypia\u201d groups","volume":"65","author":"Garc\u00eda Pascual","year":"2018","journal-title":"Endocrinol Diabetes Nutr"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0274","article-title":"Subclassification of Bethesda atypical and follicular neoplasm categories according to nuclear and architectural atypia improves discrimination of thyroid Malignancy risk","volume":"28","author":"Lim","year":"2018","journal-title":"Thyroid"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/dc.21790","article-title":"Thyroid follicular lesion of undetermined significance: Evaluation of the risk of Malignancy using the two-tier sub-classification","volume":"40","author":"Horne","year":"2012","journal-title":"Diagn Cytopathol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/dc.25261","article-title":"Two-tier subclassification of the Bethesda category III (atypia of undetermined significance\/follicular lesion of undetermined significance) in thyroid cytology","volume":"52","author":"Alden","year":"2024","journal-title":"Diagn Cytopathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2013.0317","article-title":"Malignancy rate in thyroid nodules classified as Bethesda category III (AUS\/FLUS)","volume":"24","author":"Ho","year":"2014","journal-title":"Thyroid"},{"key":"B19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejso.2015.09.026","article-title":"Risk factors associated with Malignancy and with triage to surgery in thyroid nodules classified as Bethesda category III (AUS\/FLUS)","volume":"42","author":"Kuru","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59081484","article-title":"The role of \u201ccritical\u201d ultrasound reassessment in the decision-making of Bethesda III thyroid nodules","volume":"59","author":"Orlando","year":"2023","journal-title":"Med (Kaunas)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184489","article-title":"Optimization of the management of category III thyroid nodules using repeat FNA and TIRADS","volume":"14","author":"S\u0142owi\u0144ska-Klencka","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.745395","article-title":"Malignancy rate of Bethesda class III thyroid nodules based on the presence of chronic lymphocytic thyroiditis in surgical patients","volume":"12","author":"Cho","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.21605","article-title":"A meta-analytic review of the Bethesda System for Reporting Thyroid Cytopathology: Has the rate of Malignancy in indeterminate lesions been underestimated","volume":"123","author":"Straccia","year":"2015","journal-title":"Cancer Cytopathol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/ohn.1360","article-title":"Refining the management of Bethesda III thyroid nodules by combining nuclear atypia with sonographic suspicion","volume":"173","author":"Li","year":"2025","journal-title":"Otolaryngol Head Neck Surg"},{"key":"B25","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1186\/s12957-025-04095-4","article-title":"Development of a Malignancy risk prediction model combining ultrasound and cytology for Bethesda category III thyroid nodules","volume":"23","author":"Zhang","year":"2025","journal-title":"World J Surg Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17121964","article-title":"Risk stratification for thyroid Malignancies in chronic lymphocytic thyroiditis","volume":"17","author":"Krzentowska","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-023-09842-0","article-title":"Molecular testing for thyroid nodules: Where are we now","volume":"25","author":"Ferraz","year":"2024","journal-title":"Rev Endocr Metab Disord"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2023.03.034","article-title":"Chronic lymphocytic thyroiditis may limit the utility of molecular testing in AUS\/FLUS thyroid nodules","volume":"289","author":"Remer","year":"2023","journal-title":"J Surg Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.endien.2022.02.002","article-title":"Testing of mutations on thyroid nodules with indeterminate cytology: A prospective study of 112 patients in Argentina","volume":"69","author":"Tolaba","year":"2022","journal-title":"Endocrinolog\u00eda Diabetes Y Nutrici\u00f3n"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1863739\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T05:37:57Z","timestamp":1783316277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1863739\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":29,"alternative-id":["10.3389\/fendo.2026.1863739"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1863739","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"article-number":"1863739"}}